Atomwise pioneered the use of deep convolutional neural networks for structure-based drug discovery, with its AtomNet platform applying AI to virtual screening of small molecules against protein targets. The company ran the Artificial Intelligence Molecular Screen (AIMS) academic collaboration program, partnered with biotech and pharma companies on discovery contracts, and built an internal pipeline of small-molecule programs. As of 2026, atomwise.com redirects to Numerion Labs (numerionlabs.ai), reflecting an apparent rebrand or successor entity that positions itself as an AI superplatform exploring drug-like chemical space with programs in immune and inflammatory diseases. Atomwise never exposed a public commercial API; AtomNet screening was delivered to partners as a service. The legacy GitHub organization (github.com/atomwise) hosts no public repositories.
Atomwise is profiled on the APIs.io network. Tagged areas include Drug Discovery, Biotechnology, Pharmaceuticals, Structure-Based Drug Design, and Virtual Screening.
Regulatory Posture applies to this provider. Its tags matched the
Horizontal (data, software, accessibility, platform) regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/atomwise: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: atomwise
name: Atomwise
description: Atomwise pioneered the use of deep convolutional neural networks for structure-based drug discovery, with its
AtomNet platform applying AI to virtual screening of small molecules against protein targets. The company ran the Artificial
Intelligence Molecular Screen (AIMS) academic collaboration program, partnered with biotech and pharma companies on discovery
contracts, and built an internal pipeline of small-molecule programs. As of 2026, atomwise.com redirects to Numerion Labs
(numerionlabs.ai), reflecting an apparent rebrand or successor entity that positions itself as an AI superplatform exploring
drug-like chemical space with programs in immune and inflammatory diseases. Atomwise never exposed a public commercial API;
AtomNet screening was delivered to partners as a service. The legacy GitHub organization (github.com/atomwise) hosts no
public repositories.
type: Index
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- url: https://www.atomwise.com
status: 301
note: declared website redirects to https://numerionlabs.ai/ — a different registrable domain (atomwise.com -> numerionlabs.ai),
possible rename or acquisition (probed 2026-09-03, roadmap#169)
generated: '2026-07-22'
method: derived
position: Producing
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/atomwise.png
tags:
- Drug Discovery
- Biotechnology
- Pharmaceuticals
- Structure-Based Drug Design
- Virtual Screening
- Deep Learning
- Convolutional Neural Networks
- AtomNet
- Small Molecule
- Cheminformatics
- AIMS Program
- Numerion Labs
tags_raw:
- Drug Discovery
- Biotech
- Pharmaceuticals
- Structure-Based Drug Design
- Virtual Screening
- Deep Learning
- Convolutional Neural Networks
- AtomNet
- Small Molecules
- Cheminformatics
- AIMS Program
- Numerion Labs
url: https://raw.githubusercontent.com/api-evangelist/atomwise/refs/heads/main/apis.yml
created: '2026-05-23'
modified: '2026-05-23'
specificationVersion: '0.23'
apis: []
common:
- type: DomainSecurity
url: security/atomwise-domain-security.yml
- type: Website
url: https://www.atomwise.com
- type: Successor
url: https://numerionlabs.ai
- type: GitHubOrganization
url: https://github.com/atomwise
- type: LinkedIn
url: https://www.linkedin.com/company/atomwise-inc-
- type: Twitter
url: https://twitter.com/AtomwiseInc
- type: Crunchbase
url: https://www.crunchbase.com/organization/atomwise
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →